Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

Alessandra Ferrajoli, Michael J. Keating, Susan O'Brien, Jorge Cortes, Deborah A. Thomas

Research output: Contribution to journalArticle

Abstract

Backkground: Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS). Methods: An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m2 intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with β2M level ≥ 2 mg/dL. Results: Long-term follow-up and results are reported. The overall response rate in 34 patients was 82% (9% complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74% (median follow-up, 102 months). Conclusions: Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)3182-3186
Number of pages5
JournalCancer
Volume117
Issue number14
DOIs
StatePublished - Jul 15 2011
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunotherapy
Reaction Time
Disease Progression
Morbidity
Drug Therapy
Survival
Mortality
Rituximab
Therapeutics
Serum

Keywords

  • chronic lymphocytic leukemia
  • early stage
  • rituximab
  • therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. / Ferrajoli, Alessandra; Keating, Michael J.; O'Brien, Susan; Cortes, Jorge; Thomas, Deborah A.

In: Cancer, Vol. 117, No. 14, 15.07.2011, p. 3182-3186.

Research output: Contribution to journalArticle

Ferrajoli, Alessandra ; Keating, Michael J. ; O'Brien, Susan ; Cortes, Jorge ; Thomas, Deborah A. / Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. In: Cancer. 2011 ; Vol. 117, No. 14. pp. 3182-3186.
@article{30febe8b5d064c18b39db3d5c56014d0,
title = "Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia",
abstract = "Backkground: Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS). Methods: An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m2 intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with β2M level ≥ 2 mg/dL. Results: Long-term follow-up and results are reported. The overall response rate in 34 patients was 82{\%} (9{\%} complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74{\%} (median follow-up, 102 months). Conclusions: Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.",
keywords = "chronic lymphocytic leukemia, early stage, rituximab, therapy",
author = "Alessandra Ferrajoli and Keating, {Michael J.} and Susan O'Brien and Jorge Cortes and Thomas, {Deborah A.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1002/cncr.25853",
language = "English (US)",
volume = "117",
pages = "3182--3186",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

TY - JOUR

T1 - Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

AU - Ferrajoli, Alessandra

AU - Keating, Michael J.

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Thomas, Deborah A.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Backkground: Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS). Methods: An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m2 intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with β2M level ≥ 2 mg/dL. Results: Long-term follow-up and results are reported. The overall response rate in 34 patients was 82% (9% complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74% (median follow-up, 102 months). Conclusions: Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.

AB - Backkground: Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS). Methods: An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m2 intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with β2M level ≥ 2 mg/dL. Results: Long-term follow-up and results are reported. The overall response rate in 34 patients was 82% (9% complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74% (median follow-up, 102 months). Conclusions: Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.

KW - chronic lymphocytic leukemia

KW - early stage

KW - rituximab

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=79959995569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959995569&partnerID=8YFLogxK

U2 - 10.1002/cncr.25853

DO - 10.1002/cncr.25853

M3 - Article

C2 - 21246526

AN - SCOPUS:79959995569

VL - 117

SP - 3182

EP - 3186

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -